Epithelial-Specific Deletion of 11B-Hsd2 Hinders Apc Min/þ Mouse Tumorigenesis

Li Jiang,Shilin Yang,Huiyong Yin,Xiaofeng Fan,Suwan Wang,Bing Yao,Ambra Pozzi,Xiaoping Chen,Raymond C. Harris,Ming‐Zhi Zhang
2013-01-01
Abstract:Cyclooxygenase-2 (COX-2)–derived prostaglandin E2 (PGE2) promotes colorectal tumorigenesis. Glucocorticoids are endogenous and potent COX-2 inhibitors, and their local actions are downregulated by 11bhydroxysteroid dehydrogenase type II (11b-HSD2)-mediated metabolism. Previously, it was reported that 11b-HSD2 is increased in human colonic and Apc min/þ mouse intestinal adenomas and correlated with increased COX-2, and 11b-HSD2 inhibition suppressed the COX-2 pathway and decreased tumorigenesis. Because 11bHSD2 is expressed in Apc min/þ mouse intestinal adenoma stromal and epithelial cells, Apc min/þ mice were generated with selective deletion of 11b-HSD2 in intestinal epithelial cells (Vil-Cre-HSD2 � /� Apc min/þ ). Deletion of 11b-HSD2 in intestinal epithelia led to marked inhibition of Apc min/þ mouse intestinal tumorigenesis. Immunostaining indicated decreased 11b-HSD2 and COX-2 expression in adenoma epithelia, whereas stromalCOX-2expressionwasintactinVil-Cre-HSD2 � /� Apc min/þ mice.InVil-Cre-HSD2 � /� Apc min/þ mouse intestinal adenomas, both p53 and p21 mRNA and protein were increased, with a concomitant decrease in pRb, indicating glucocorticoid-mediated G1-arrest. Further study revealed that REDD1 (regulated in development and DNA damage responses 1), a novel stress-induced gene that inhibits mTOR signaling, was increased, whereas the mTOR signaling pathway was inhibited. Therefore, in Vil-Cre-HSD2 � /� Apc min/þ mice, epithelial cell 11b-HSD2 deficiency leads to inhibition of adenoma initiation and growth by attenuation of COX-2 expression, increasedcell-cycle arrest,andinhibitionofmTOR signalingasaresult ofincreasedtumorintracellular active glucocorticoids. Implications: Inhibition of 11b-HSD2 may represent a novel approach for colorectal cancer chemoprevention by increasing tumor glucocorticoid activity, whic hi n turn inhibits tumor growth by multiple pathways. Mol Cancer Res; 11(9); 1040–50. � 2013 AACR.
What problem does this paper attempt to address?